Amgen ($AMGN) rarely details much on international sales but did give a bit of background on Vectibix in Japan on the July 30 earnings call.
Tony Hooper, head of Global Commercial Operations, noted exceptioaln sales connected to the expansion of Vectibix into earlier lines of therapy in metastatic colorectal cancer in both the U.S. and Europe.
"We continue to see unit growth in the U.S. of close to 40% and in Europe of nearly 10%," Hooper said.
But he also noted that Amgen's partner in Japan, Takeda Pharmaceutical, also benefitted.
"The second quarter was also positively impacted by timing of shipments to our Japanese partner," Hooper said.
Bob Bradway, chairman and CEO, said that a global regulatory push is underway for AMG 416. In May, the company said reported positive pivotal data from a Phase III trial on the candidate to treat secondary hyperparathyroidism in patients with chronic kidney disease receiving hemodialysis.